Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen - Cho, Hee-Jeong; Seo, Sang-Kyung; Baek, Dong Won; Park, Sung-Woo; Lee, Yoo-Jin; Sohn, Sang-Kyun; Lee, Ho-Sup; Lee, Won Sik; Lee, Ji Hyun; Kim, Sung Hyun; Moon, Joon-Ho (Journal of yeungnam medical science, 2018)
Keywords: Bortezomib; Elderly; Medication adherence; Multiple myeloma; Original; 의학일반